Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Income Statement
Quarterly Data

Regeneron Pharmaceuticals Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales 53.92 53.12 56.11 52.75 49.77 61.35 61.40 55.26 80.28 66.03 80.53 68.19 66.94 64.61 62.85 67.65 59.29 60.45 62.33 64.52
Collaboration revenue 39.89 42.77 41.69 43.58 46.49 35.78 36.53 41.57 17.98 31.10 18.58 29.83 27.97 28.47 26.30 28.90 34.47 34.51 33.00 30.53
Other revenue 6.19 4.11 2.19 3.67 3.74 2.87 2.07 3.17 1.74 2.87 0.90 1.98 5.09 6.91 10.85 3.46 6.23 5.03 4.67 4.95
Revenues 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of goods sold -8.93 -6.68 -6.09 -6.59 -8.85 -4.81 -5.22 -6.99 -16.39 -6.92 -10.50 -7.24 -7.41 -5.71 -5.25 -4.31 -5.00 -5.66 -3.46 -4.14
Cost of collaboration and contract manufacturing -6.12 -6.30 -6.73 -7.88 -6.98 -6.01 -5.18 -6.66 -3.45 -6.21 -3.00 -4.94 -7.16 -6.23 -8.86 -7.58 -5.32 -5.40 -4.42 -6.33
Cost of revenues -15.05% -12.98% -12.82% -14.47% -15.83% -10.82% -10.40% -13.66% -19.84% -13.13% -13.50% -12.18% -14.57% -11.94% -14.11% -11.89% -10.32% -11.06% -7.89% -10.47%
Gross profit 84.95% 87.02% 87.18% 85.53% 84.17% 89.18% 89.60% 86.34% 80.16% 86.87% 86.50% 87.82% 85.43% 88.06% 85.89% 88.11% 89.68% 88.94% 92.11% 89.53%
Research and development -34.28 -31.98 -34.37 -34.82 -30.55 -31.04 -27.80 -28.46 -14.90 -19.27 -13.90 -29.38 -30.73 -29.84 -36.99 -31.94 -31.49 -32.39 -54.21 -37.49
Acquired in-process research and development -0.87 -2.97 0.00 -1.77 -0.88 0.00 -6.89 -0.95 -0.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Selling, general, and administrative -21.48 -19.05 -20.65 -19.01 -19.34 -18.02 -16.67 -15.18 -11.30 -12.89 -8.07 -16.04 -12.53 -14.25 -17.84 -20.09 -27.05 -20.50 -21.58 -24.00
Other operating income (expense), net 0.01 0.01 0.02 0.02 0.19 1.56 0.61 0.68 0.32 -1.22 0.61 1.60 5.99 1.94 2.57 2.21 0.00 0.00 0.00 0.00
Income from operations 28.33% 33.04% 32.19% 29.94% 33.59% 41.68% 38.85% 42.44% 53.31% 53.50% 65.14% 44.00% 48.17% 45.91% 33.63% 38.29% 31.15% 36.05% 16.32% 28.04%
Other income (expense), net 5.62 0.52 2.70 -2.24 5.72 10.26 -4.68 -6.20 -2.47 -0.47 8.17 6.13 2.99 -1.24 13.94 -1.39 10.18 1.85 -4.29 4.31
Interest expense -0.53 -0.53 -0.60 -0.57 -0.51 -0.52 -0.46 -0.46 -0.28 -0.41 -0.28 -0.58 -0.61 -1.15 -0.50 -0.33 -0.31 -0.38 -0.41 -0.45
Other income (expense) 5.09% -0.01% 2.10% -2.81% 5.21% 9.74% -5.13% -6.66% -2.75% -0.89% 7.89% 5.55% 2.38% -2.39% 13.45% -1.72% 9.87% 1.46% -4.70% 3.86%
Income before income taxes 33.42% 33.03% 34.29% 27.13% 38.80% 51.42% 33.71% 35.79% 50.56% 52.61% 73.03% 49.55% 50.54% 43.52% 47.07% 36.57% 41.01% 37.52% 11.62% 31.90%
Income tax expense 0.35 -3.06 -3.63 -1.27 -3.74 -6.61 -3.89 -2.95 -5.54 -5.34 -12.73 -5.45 -3.11 -6.81 -1.11 -2.41 -4.51 -4.83 -1.63 -4.97
Net income 33.77% 29.97% 30.66% 25.86% 35.06% 44.81% 29.82% 32.83% 45.01% 47.27% 60.31% 44.10% 47.43% 36.71% 45.97% 34.16% 36.51% 32.69% 9.99% 26.94%

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Income from operations The net result for the period of deducting operating expenses from operating revenues. Regeneron Pharmaceuticals Inc. income from operations as a percentage of revenues increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Regeneron Pharmaceuticals Inc. income before income taxes as a percentage of revenues decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Regeneron Pharmaceuticals Inc. net income as a percentage of revenues decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.